PDF(Sci-hub)
Abstract：
Severe bronchial asthma is a challenging disorder to treat and can impair quality of life (QOL) under conventional therapeutic modalities. We report the case of a 52-year-old woman with severe asthma associated with eosinophilic chronic rhinosinusitis (ECRS) and eosinophilic otitis media (EOM). Although the patient was treated with a full dose of inhaled corticosteroid, leukotriene receptor antagonist (LTRA), theophylline, burst use of oral corticosteroids (OCS), her asthmatic condition aggravated, disrupting her daily life. ECRS and EOM symptoms were also getting worse despite treatment with topical application of corticosteroids to the nose and ears, LTRA, and occasional use of OCS. In addition to asthmatic symptom, the patient always suffered from intractable nasal obstruction and hearing disturbance, which contributed to the heavily impaired QOL. However, the administration of benralizumab showed rapid and remarkable improvement not only in her asthmatic conditions but also in the symptoms of ECRS and EOM within a month. These results suggest that the use of benralizumab for the treatment of severe asthma with intractable ECRS and EOM should be considered when the patient\'s QOL is severely deteriorated.
摘要：
严重的支气管哮喘是一种具有挑战性的疾病，在常规治疗方式下可能会损害生活质量（QOL）。我们报告了一例52岁女性，患有与嗜酸性粒细胞性慢性鼻-鼻窦炎（ECRS）和嗜酸性粒细胞性中耳炎（EOM）相关的严重哮喘。尽管患者接受了全剂量的吸入性皮质类固醇治疗，白三烯受体拮抗剂（LTRA），茶碱,口服皮质类固醇（OCS）的爆发使用，她的哮喘病加重了,扰乱了她的日常生活.ECRS和EOM症状也变得更糟，尽管治疗与局部应用皮质类固醇的鼻子和耳朵，LTRA,偶尔使用OCS。除了哮喘症状,患者总是患有顽固性鼻塞和听力障碍，导致QOL严重受损。然而,贝那利珠单抗的给药在1个月内不仅对哮喘患者的病情,而且对ECRS和EOM的症状也有了快速和显著的改善.这些结果表明，当患者的生活质量严重恶化时，应考虑使用贝那利珠单抗治疗患有难治性ECRS和EOM的重度哮喘。
